Home > Animal Health & Nutrition > Veterinary Pharmaceuticals > Veterinary Dermatology Drugs Market

Veterinary Dermatology Drugs Market Trends

Report ID: GMI6332
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Veterinary Dermatology Drugs Market Trends

Several trends were shaping the market includes the growing trend of pet humanization and increased awareness about pet health has led to a higher demand for specialized veterinary dermatology drugs, rising emphasis on preventive care, including dermatological health, increasing investments in research and development to improve drug formulations for veterinary dermatology, rising prevalence of allergies, such as atopic dermatitis, the increasing adoption of telemedicine and e-commerce in veterinary care, and rising adoption of pet insurance. These above factors are driving the market trends.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The veterinary dermatology drugs industry size was valued to be USD 7.3 billion in 2022 and is expected to record a CAGR of 9.5% from 2023 to 2032 owing to the rising incidence of skin disorders in animals.

The oral segment was worth USD 3.4 billion in 2022 and is expected to grow at 9.2% CAGR through 2032 as this route of administration provides a systemic approach to dermatological disorders, allowing the medication to circulate through the body and address the underlying source of the problem.

North America veterinary dermatology drugs market is expected to reach USD 6.9 billion by 2032 as the region has a significant number of veterinary dermatology specialists who focus on diagnosing and treating skin conditions in animals.

Elanco Animal Health Incorporated, Vetoquinol S.A., Ceva, Merck & Co., Inc., Zoetis, Inc., Virbac, Bimeda, Inc., Vivaldis, Bioiberica S.A.U, and Indian Immunologicals Ltd.